Similar articles

• Orphan drugs and the NHS: should we value rarity?

  McCabe C, Claxton K, Tsuchiya A. McCabe C, et al. BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016. BMJ. 2005. PMID: 16254305 Free PMC article. Review.
• Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.

  Sheehan M. Sheehan M. BMJ. 2005 Nov 12;331(7525):1144-5. doi: 10.1136/bmj.331.7525.1144-c. BMJ. 2005. PMID: 16282416 Free PMC article. No abstract available.
• [Orphan drugs: drugs for rare diseases].

  Schenk M. Schenk M. Dtsch Med Wochenschr. 2010 May;135(18):p17. Dtsch Med Wochenschr. 2010. PMID: 20455291 German. No abstract available.
• Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.

  Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Simoens S, et al. Appl Health Econ Health Policy. 2013 Feb;11(1):1-3. doi: 10.1007/s40258-012-0004-y. Appl Health Econ Health Policy. 2013. PMID: 23329382 No abstract available.
• The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.

  Kumar Kakkar A, Dahiya N. Kumar Kakkar A, et al. Drug Dev Res. 2014 Jun;75(4):231-4. doi: 10.1002/ddr.21176. Epub 2014 May 14. Drug Dev Res. 2014. PMID: 24829189 Review.